BioSpace News Archive

Antares Pharma, Inc., a pharmaceutical technology company, announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020.

Clearside Biomedical, Inc., a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced that its second quarter 2020 financial results will be reported on Monday, August 10, 2020 after the close of the financial markets.

iRadimed Corporation announced financial results for the three and six months ended June 30, 2020.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present initial clinical data on the first five patients from Part B of the ongoing Phase 1/2a study, which explores the combination of Genocea’s neoantigen vaccine, GEN-009 and checkpoint inhibitor-based regimens in advanced solid tumors.

Phase 1 Single Ascending Dose Study is Intended to Support the Clinical Development of SYN-020 in Multiple Indications

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the promotion of Antoine ‘Tony’ Awad to the position of Chief Operating Officer.

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced that the Company has initiated site screening of long term care facilities in Ontario for its Phase 2 study evaluating favipiravir as a post-exposure outbreak control measure against COVID-19.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the abstract on study results of its first pediatric study on macimorelin has been selected for presentation at the 22nd European Congress of Endocrinology (e-ECE 2020) being held September 5-9, 2020.

Ipsen, a global specialty-driven biopharmaceutical group, announced financial results for the first half of 2020.

AAIC 2020 Highlights New Research Linking Flu, Pneumonia Vaccination & Low Early-Life BMI with Reduced Risk of Alzheimer’s and Dementia